Physician profile
Amber A Maynard
NPI 1497389233
$5,618.14
in general payments reported to CMS, 2019-2025
24 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what 89% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $749 · 2022: $1,073 · 2023: $1,902 · 2024: $754 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,525 · Travel and Lodging: $209 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,525.35 |
| Travel and Lodging | $208.52 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $901.23 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $797.88 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $789.56 | 2021-2024 | Xarelto |
| Medtronic, INC. | $499.49 | 2021-2025 | Symplicity G3 |
| Merck Sharp & Dohme LLC | $383.44 | 2021-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $346.95 | 2021-2025 | |
| Amgen INC. | $331.81 | 2021-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $325.24 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $274.12 | 2022-2023 | Farxiga, Brilinta, Atacand |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.90 | 2021-2025 | Jardiance |
| Pfizer INC. | $200.03 | 2021-2025 | |
| Inari Medical, INC. | $199.56 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Shockwave Medical, INC | $94.90 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Alnylam Pharmaceuticals INC. | $39.48 | 2024-2025 | Onpattro |
| Baxter Healthcare | $35.51 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $31.98 | 2023-2024 | Inpefa |
| Philips North America LLC | $29.63 | 2022-2023 | |
| Cvrx, INC. | $26.35 | 2022-2023 | Barostim Neo System |
| Inogen, INC. | $18.96 | 2024 | |
| Inspire Medical Systems, INC. | $17.33 | 2023 | Inspire |
| Edwards Lifesciences Corporation | $15.71 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $15.03 | 2024 | Arcalyst |
| Vital Connect, INC | $14.77 | 2025 | Vitalpatch Rtm |
| Amarin Pharma, INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Maynard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.